抗生素暴露与新发炎症性肠病风险:系统综述与剂量反应Meta分析
该系统综述与Meta分析检索4个数据库至2023年9月30日,纳入28项研究共153,027例炎症性肠病患者,评估抗生素暴露与新发炎症性肠病风险的关联。处方数据库研究中合并OR为1.41(95%CI 1.29-1.53),问卷研究中合并OR为1.35(95%CI 1.08-1.68),并观察到抗生素处方数与风险间的正向非线性剂量反应关系。
要点
- 抗生素暴露与新发炎症性肠病风险升高相关,处方研究合并OR 1.41(95%CI 1.29-1.53)。
- 甲硝唑OR 1.70(95%CI 1.38-2.10)和喹诺酮类OR 1.56(95%CI 1.37-1.77)风险估计相对较高。
- 抗生素处方数与炎症性肠病风险呈正向非线性剂量反应关系。
核心结论
- 抗生素暴露与新发炎症性肠病风险显著相关,并观察到正向非线性剂量反应关系,抗生素管理可能对降低炎症性肠病风险重要。
研究设计与样本
- 系统综述与Meta分析,检索4个数据库自建库至2023年9月30日的相关研究,纳入28项研究共153,027例炎症性肠病患者。
主要发现
- 处方数据库研究中抗生素暴露与新发炎症性肠病风险升高相关,合并OR 1.41(95%CI 1.29-1.53)。
- 问卷研究中抗生素暴露与新发炎症性肠病风险升高相关,合并OR 1.35(95%CI 1.08-1.68)。
- 该关联在克罗恩病和溃疡性结肠炎中均存在,在处方数据库研究的儿童和成人中亦存在。
- 多数抗生素类别与炎症性肠病风险升高相关,甲硝唑OR 1.70(95%CI 1.38-2.10),喹诺酮类OR 1.56(95%CI 1.37-1.77)。
- 抗生素处方数与炎症性肠病风险之间观察到正向非线性剂量反应关联。
关键数值与推荐
- 处方数据库研究合并OR 1.41(95%CI 1.29-1.53)。
- 问卷研究合并OR 1.35(95%CI 1.08-1.68)。
- 甲硝唑OR 1.70(95%CI 1.38-2.10)。
- 喹诺酮类OR 1.56(95%CI 1.37-1.77)。
临床怎么用
- 原文结论指出抗生素管理可能对降低炎症性肠病风险重要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The association between antibiotic exposure and inflammatory bowel disease (IBD) remains controversial, especially whether there is a dose-response relationship. We aimed to conduct a systematic review and meta-analysis to thoroughly evaluate the risk of new-onset IBD associated with antibiotic exposure. METHODS: Four databases were searched from their inception to September 30, 2023 for all relevant studies. The risk estimates were pooled together using random-effects models, and pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated, stratified by IBD subtype, age, exposure period, study type, and antibiotic classes. Dose-response relationship between the number of antibiotic prescriptions and IBD risk was assessed using generalized least squares regression analysis. RESULTS: Twenty-eight studies involving 153,027 patients with IBD were included. Antibiotic exposure was significantly associated with an increased risk of new-onset IBD for prescription-based studies (pooled OR, 1.41; 95% CI, 1.29-1.53) and for questionnaire-based studies (pooled OR, 1.35; 95% CI, 1.08-1.68). This association existed for both Crohn's disease and ulcerative colitis, as well as in children and adults for prescription-based studies. The majority of antibiotic classes were associated with an increased IBD risk, with metronidazole (OR, 1.70; 95% CI, 1.38-2.10) and quinolones (OR, 1.56; 95% CI, 1.37-1.77) having relatively higher risk estimates. A positive nonlinear dose-response association was observed between the number of antibiotic prescriptions and IBD risk. CONCLUSIONS: Antibiotic exposure was significantly associated with an increased risk of new-onset IBD, and a positive nonlinear dose-response relationship was observed. Antibiotic stewardship may be important for reducing IBD risk.
引用
- Duan R, Zhang C, Li G, et al. Antibiotic Exposure and Risk of New-Onset Inflammatory Bowel Disease: A Systematic Review and Dose-Response Meta-Analysis. Clin Gastroenterol Hepatol. 2024. PMID: 38423349. doi:10.1016/j.cgh.2024.02.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。